Genentech Announces Positive Phase II Results for Its Dual GLP-1/GIP Receptor Agonist CT-388 in People Living With Obesity 27 January
Genentech More than Doubles Investment in Holly Springs, North Carolina Manufacturing Facility 20 January
Genentech More than Doubles Investment in Holly Springs, North Carolina Manufacturing Facility 20 January
